Thu Apr 30 2020

suPAR is an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

This study published in Critical Care by Nikoletta Rovina, MD, Ph.D. et al, may be of major importance in the management of COVID-19.

The study shows that suPAR (soluble urokinase plasminogen activator receptor) can act as an early predictor of the risk of severe respiratory failure in patients with COVID-19.

The baseline suPAR level can differentiate whether patients with COVID-19 will have a mild or a severe outcome of the infection.
This can aid in selecting which COVID-19 patients may be sent home (home quarantine) and which patients should be admitted to the hospital.

Link to publication in Critical Care here

At the beginning of the illness, patients may experience low-degree fever or flu-like symptoms.
While some patients have a mild or moderate course of the disease, others progress to severe respiratory failure and mechanical ventilation (respirator) is needed to save the patient.

The study asked whether suPAR, measured at admission, can predict which patients will develop severe respiratory failure and which will not.

Measured suPAR levels from Greek COVID-19 patients by The Hellenic Sepsis Study Group were similar to those collected from patients with COVID-19 from the Emergency Department (ED) of Rush University Medical Center (USA). Patients were followed for 14 days after admission.

The results showed that admission levels of suPAR were significantly greater among patients who eventually developed severe respiratory failure.

Patients with suPAR above 6 ng/ml upon admission, had a 16 times higher risk of respiratory failure, than patients with suPAR below 6 ng/ml.

Conclusion:

The study shows that baseline plasma suPAR level can differentiate whether patients with COVID-19 will have a mild or a severe outcome of the infection.

This can aid in selecting which COVID-19 patients may be sent home and which patients should be admitted to the hospital.

Link to publication in Critical Care here

Link to Press Release from ViroGates here

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates